Andrew J. Einhorn

CIK 1560685 · Chief Financial Officer · last filed 2025-12-29

Andrew J. Einhorn is a Chief Financial Officer who has filed 11 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for PTHS, was dated Dec 29, 2025. Across all open-market trades the lifetime net is +$495.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.55M

Companies

4

Total Filings

11

Lifetime Open-Market Net

$495.0K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PTHS Director 12,000 $27.50 $330.0K $0 1 2025-12-29
RVL Pharmaceuticals plc (RVLP) Delisted Chief Financial Officer 164,325 $0.03 $4.6K $0 1 2022-01-26
RVL Pharmaceuticals plc (OSMT) Delisted Chief Financial Officer 173,932 $1.11 $193.1K $0 6 2021-11-08
EDGE Chief Financial Officer 126,815 $49.07 $6.22M $495.0K 3 2017-03-13

Recent Filings

11 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2025-12-29 PTHS Grant (A) +12,000 $0 EDGAR
2022-01-26 RVL Pharmaceuticals plc (RVLP) Delisted Tax (F) −9,607 -$10.9K EDGAR
2021-11-08 RVL Pharmaceuticals plc (OSMT) Delisted Grant (A) $0 EDGAR
2021-05-20 RVL Pharmaceuticals plc (OSMT) Delisted Tax (F) −6,467 -$20.2K EDGAR
2021-01-26 RVL Pharmaceuticals plc (OSMT) Delisted Tax (F) −9,668 -$43.1K EDGAR
2020-05-20 RVL Pharmaceuticals plc (OSMT) Delisted Grant (A) +71,550 $0 EDGAR
2020-01-30 RVL Pharmaceuticals plc (OSMT) Delisted Tax (F) −9,184 -$64.3K EDGAR
2019-01-28 RVL Pharmaceuticals plc (OSMT) Delisted Grant (A) +104,849 $0 EDGAR
2017-03-13 EDGE Exer (X) +1,567 $3.7K EDGAR
2016-02-18 EDGE Grant (A) $0 EDGAR
Showing 110 of 11
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.